Skip to content
2000
Volume 4, Issue 2
  • ISSN: 2210-3090
  • E-ISSN: 2210-3104

Abstract

Helicobacter pylori are the main cause of gastritis, peptic ulceration and distal gastric adenocarcinoma. Bacterial virulence factors actively contribute in the clinical outcome and progression of Helicobacter pylori infection. The wide range of digestive disease attributed with Helicobacter pylori infection has led scientists to a huge interest in biomarkers. Thus, determination of a biomarker as practical patent for each infectious disease needs a logical clinical set up. Identification of a validated biomarker for Helicobacter pylori calls further investigations including in vitro and in vivo experiments. Undoubtedly, determination of best available biomarker such as dupA can help physicians to go one step further to manage persistent colonizsation of Helicobacter pylori.

Loading

Article metrics loading...

/content/journals/rpbm/10.2174/2210309004666140901221522
2014-05-01
2025-09-24
Loading full text...

Full text loading...

/content/journals/rpbm/10.2174/2210309004666140901221522
Loading

  • Article Type:
    Research Article
Keyword(s): Biomarkers; cagA; clinical outcome; dupA; Helicobacter pylori; oipA
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test